Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia

The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilich, Anton, Gernsheimer, Terry B., Triulzi, Darrell J., Herren, Heather, Brown, Siobhan P., Holle, Lori A., Lucas, Andrew T., de Laat, Bas, El Kassar, Nahed, Wolberg, Alisa S., May, Susanne, Key, Nigel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Thrombosis and Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025092/
https://www.ncbi.nlm.nih.gov/pubmed/36044391
http://dx.doi.org/10.1182/bloodadvances.2022008255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025092/
https://www.ncbi.nlm.nih.gov/pubmed/36044391
http://dx.doi.org/10.1182/bloodadvances.2022008255

Ejemplares similares